Table 11.

Differences in the IDSA and ESCMID S. maltophilia infections treatment recommendations. Adapted from Tamma et al. [163] and Carrara et al. [178]

IDSA	ESCMID
We recommend the use of 2 of the following antibiotics in combination: TMP-SMX, minocycline, tigecycline, cefiderocol or levofloxacin.	Consider combined therapy in severe infections, especially in immunocompromised patients.
We recommend the combination ceftazidime-avibactam plus aztreonam in clinical instability, intolerance, or resistance to other alternatives.	In patients with infections resistant to TMP-SMX or if it cannot be used, perform combined treatment based on in vitro activity.
Use TMP-SMX 8-12mg/kg (TMP) in combination therapy, at least until clinical improvement.	Use TMP-SMX at 15mg/Kg/day (TMP) in 3-4 doses adjusted to renal function.
High doses of minocycline (200mg/12h) in combination therapy is reasonable, until clinical improvement. Tigecycline is a sensible option.	Levofloxacin monotherapy is non-inferior to TMP-SMX monotherapy. If fluoroquinolones are used, emergence of resistance during treatment may appear.
We recommend cefiderocol in combined therapy until clinical improvement.	In patients with limited options consider second-line agents based on in vitro test.
Use levofloxacin as part of combination therapy. It is not advised leave it on monotherapy after clinical improvement.